Hormone Replacement Therapy MarketThe global hormone replacement therapy (HRT) market is poised for steady growth, with a projected compound annual growth rate (CAGR) of 3.5%. From an estimated market ...

QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company sees ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

The growing demand for fast and effective sinusitis treatments is expected to drive further innovations in pharmaceuticals and medical devices. Increasing awareness, advancements in drug formulations ...

USA News Group News Commentary ? As the new administration starts to make its mark in the United States, President Trump recently announced a $500 billion AI infrastructure investment in the country, ...

A new study suggests clinical utility of the first FDA-approved genetic test to help gauge an individual’s risk for opioid ...

Exchange Traded Concepts LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 3.5% during ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was the recipient of some unusual options trading on Monday.